General MedicationsORALStandard
LENVIMA
LENVATINIB MESYLATE
Standard Dose
EQ 10MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview LENVIMA is listed in Drugs@FDA under application 206947 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient LENVATINIB MESYLATE Form and strength CAPSULE;ORAL - EQ 10MG BASE Sponsor EISAI INC Submission history Latest submission status date: 2025-01-29 00:00:00.
Structured Monograph
Clinical summary
Approval overview LENVIMA is listed in Drugs@FDA under application 206947 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LENVATINIB MESYLATE Form and strength CAPSULE;ORAL - EQ 10MG BASE Sponsor EISAI INC Submission history Latest submission status date: 2025-01-29 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.